| pubmed-article:17878499 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17878499 | lifeskim:mentions | umls-concept:C0019196 | lld:lifeskim |
| pubmed-article:17878499 | lifeskim:mentions | umls-concept:C0599755 | lld:lifeskim |
| pubmed-article:17878499 | lifeskim:mentions | umls-concept:C0036341 | lld:lifeskim |
| pubmed-article:17878499 | lifeskim:mentions | umls-concept:C0009079 | lld:lifeskim |
| pubmed-article:17878499 | lifeskim:mentions | umls-concept:C0220908 | lld:lifeskim |
| pubmed-article:17878499 | lifeskim:mentions | umls-concept:C0596545 | lld:lifeskim |
| pubmed-article:17878499 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17878499 | pubmed:dateCreated | 2007-9-19 | lld:pubmed |
| pubmed-article:17878499 | pubmed:abstractText | Hepatitis C virus (HCV) infection occurs in up to 20% of patients with chronic mental illnesses. To determine the prevalence of hepatitis C in a diagnostically well-defined sample, the authors screened all schizophrenia outpatients in a clozapine clinic (N=98) for HCV antibodies. Eight patients were positive for hepatitis C antibodies (antibody-positive prevalence: 8.2%); of those, 50% had detectable viral loads (viremia-positive prevalence: 4.1%). Screening for HCV infection should be considered for outpatients with schizophrenia. However, clinical experience treating HCV in schizophrenia patients is limited; in this cohort, 2 years after screening, no patient had received interferon/ribavirin treatment. | lld:pubmed |
| pubmed-article:17878499 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17878499 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17878499 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17878499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17878499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17878499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17878499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17878499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17878499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17878499 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17878499 | pubmed:issn | 0033-3182 | lld:pubmed |
| pubmed-article:17878499 | pubmed:author | pubmed-author:GandhiRajesh... | lld:pubmed |
| pubmed-article:17878499 | pubmed:author | pubmed-author:HendersonDavi... | lld:pubmed |
| pubmed-article:17878499 | pubmed:author | pubmed-author:GoffDonald... | lld:pubmed |
| pubmed-article:17878499 | pubmed:author | pubmed-author:FreudenreichO... | lld:pubmed |
| pubmed-article:17878499 | pubmed:author | pubmed-author:WalshJared... | lld:pubmed |
| pubmed-article:17878499 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17878499 | pubmed:volume | 48 | lld:pubmed |
| pubmed-article:17878499 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17878499 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17878499 | pubmed:pagination | 405-11 | lld:pubmed |
| pubmed-article:17878499 | pubmed:meshHeading | pubmed-meshheading:17878499... | lld:pubmed |
| pubmed-article:17878499 | pubmed:meshHeading | pubmed-meshheading:17878499... | lld:pubmed |
| pubmed-article:17878499 | pubmed:meshHeading | pubmed-meshheading:17878499... | lld:pubmed |
| pubmed-article:17878499 | pubmed:meshHeading | pubmed-meshheading:17878499... | lld:pubmed |
| pubmed-article:17878499 | pubmed:meshHeading | pubmed-meshheading:17878499... | lld:pubmed |
| pubmed-article:17878499 | pubmed:meshHeading | pubmed-meshheading:17878499... | lld:pubmed |
| pubmed-article:17878499 | pubmed:meshHeading | pubmed-meshheading:17878499... | lld:pubmed |
| pubmed-article:17878499 | pubmed:meshHeading | pubmed-meshheading:17878499... | lld:pubmed |
| pubmed-article:17878499 | pubmed:meshHeading | pubmed-meshheading:17878499... | lld:pubmed |
| pubmed-article:17878499 | pubmed:meshHeading | pubmed-meshheading:17878499... | lld:pubmed |
| pubmed-article:17878499 | pubmed:meshHeading | pubmed-meshheading:17878499... | lld:pubmed |
| pubmed-article:17878499 | pubmed:meshHeading | pubmed-meshheading:17878499... | lld:pubmed |
| pubmed-article:17878499 | pubmed:meshHeading | pubmed-meshheading:17878499... | lld:pubmed |
| pubmed-article:17878499 | pubmed:meshHeading | pubmed-meshheading:17878499... | lld:pubmed |
| pubmed-article:17878499 | pubmed:meshHeading | pubmed-meshheading:17878499... | lld:pubmed |
| pubmed-article:17878499 | pubmed:meshHeading | pubmed-meshheading:17878499... | lld:pubmed |
| pubmed-article:17878499 | pubmed:articleTitle | Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort. | lld:pubmed |
| pubmed-article:17878499 | pubmed:affiliation | Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, the Division of Infectious Diseases and Partners AIDS Research Center, and Harvard Medical School, Boston, MA 02114, USA. ofreudenreich@partners.org | lld:pubmed |
| pubmed-article:17878499 | pubmed:publicationType | Journal Article | lld:pubmed |
